EdgarLookup

ALBANY INTERNATIONAL CORP /DE/ — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that ALBANY INTERNATIONAL CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-22.3%
Profit Margin
Net income ÷ revenue
-3.3%
Return on Assets
Net income ÷ assets
1.36x
Debt-to-Equity
Total liabilities ÷ equity
-4.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2019 $257.70M Feb 28, 2020
FY2019 Sep 30, 2019 $271.10M Feb 28, 2020
FY2019 Jun 30, 2019 $273.90M Feb 28, 2020
FY2019 Mar 31, 2019 $251.40M Feb 28, 2020
FY2019 Dec 31, 2018 $251.60M Feb 28, 2020
FY2019 Sep 30, 2018 $251.90M Feb 28, 2020
FY2019 Jun 30, 2018 $255.40M Feb 28, 2020
FY2019 Mar 31, 2018 $223.60M Feb 28, 2020
FY2019 Dec 31, 2017 $226.70M Feb 28, 2020
FY2019 Sep 30, 2017 $222.10M Feb 28, 2020

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.18B Feb 27, 2026
FY2025 Dec 31, 2024 $1.23B Feb 27, 2026
FY2025 Dec 31, 2023 $1.15B Feb 27, 2026
FY2024 Dec 31, 2022 $1.03B Feb 26, 2025
FY2023 Dec 31, 2021 $929.24M Feb 26, 2024
FY2022 Dec 31, 2020 $900.61M Feb 24, 2023
FY2021 Dec 31, 2019 $1.05B Feb 25, 2022
FY2020 Dec 31, 2018 $982.48M Feb 25, 2021

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $243.92M Feb 27, 2026
FY2025 Dec 31, 2024 $401.78M Feb 27, 2026
FY2025 Dec 31, 2023 $423.72M Feb 27, 2026
FY2024 Dec 31, 2022 $389.78M Feb 26, 2025
FY2023 Dec 31, 2021 $378.39M Feb 26, 2024
FY2022 Dec 31, 2020 $371.07M Feb 24, 2023
FY2019 Dec 31, 2019 $96.60M Feb 28, 2020
FY2019 Sep 30, 2019 $104.10M Feb 28, 2020
FY2019 Jun 30, 2019 $105.20M Feb 28, 2020
FY2019 Mar 31, 2019 $91.80M Feb 28, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($57.34M) Feb 27, 2026
FY2025 Dec 31, 2024 $87.62M Feb 27, 2026
FY2025 Dec 31, 2023 $111.12M Feb 27, 2026
FY2024 Dec 31, 2022 $95.76M Feb 26, 2025
FY2023 Dec 31, 2021 $118.48M Feb 26, 2024
FY2022 Dec 31, 2020 $98.59M Feb 24, 2023
FY2019 Dec 31, 2019 $29.10M Feb 28, 2020
FY2019 Sep 30, 2019 $40.00M Feb 28, 2020
FY2019 Jun 30, 2019 $34.10M Feb 28, 2020
FY2019 Mar 31, 2019 $29.20M Feb 28, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($36.10M) Feb 27, 2026
FY2025 Dec 31, 2024 $131.36M Feb 27, 2026
FY2025 Dec 31, 2023 $167.89M Feb 27, 2026
FY2024 Dec 31, 2022 $181.02M Feb 26, 2025
FY2023 Dec 31, 2021 $178.01M Feb 26, 2024
FY2022 Dec 31, 2020 $166.08M Feb 24, 2023
FY2021 Dec 31, 2019 $193.58M Feb 25, 2022
FY2018 Dec 31, 2018 $37.40M Mar 14, 2019
FY2018 Sep 30, 2018 $40.80M Mar 14, 2019
FY2018 Jun 30, 2018 $42.20M Mar 14, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2023 $40.60M Feb 26, 2024
FY2023 Dec 31, 2022 $39.90M Feb 26, 2024
FY2023 Dec 31, 2021 $38.90M Feb 26, 2024
FY2022 Dec 31, 2020 $25.80M Feb 24, 2023
FY2021 Dec 31, 2019 $26.90M Feb 25, 2022
FY2020 Dec 31, 2018 $29.80M Feb 25, 2021
FY2019 Dec 31, 2017 $30.70M Feb 28, 2020
FY2018 Dec 31, 2016 $28.80M Mar 14, 2019
FY2017 Dec 31, 2015 $31.70M Feb 28, 2018
FY2016 Dec 31, 2014 $32.40M Mar 1, 2017

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $218.33M Feb 27, 2026
FY2025 Dec 31, 2024 $210.88M Feb 27, 2026
FY2025 Dec 31, 2023 $214.92M Feb 27, 2026
FY2024 Dec 31, 2022 $168.71M Feb 26, 2025
FY2023 Dec 31, 2021 $160.13M Feb 26, 2024
FY2022 Dec 31, 2020 $163.91M Feb 24, 2023
FY2021 Dec 31, 2019 $163.65M Feb 25, 2022
FY2020 Dec 31, 2018 $156.19M Feb 25, 2021
FY2019 Dec 31, 2017 $162.94M Feb 28, 2020
FY2018 Dec 31, 2016 $158.36M Mar 14, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $152.47M Feb 27, 2026
FY2025 Dec 31, 2024 $218.44M Feb 27, 2026
FY2025 Dec 31, 2023 $148.06M Feb 27, 2026
FY2024 Dec 31, 2022 $128.21M Feb 26, 2025
FY2023 Dec 31, 2021 $217.48M Feb 26, 2024
FY2022 Dec 31, 2020 $140.25M Feb 24, 2023
FY2021 Dec 31, 2019 $200.35M Feb 25, 2022
FY2020 Dec 31, 2018 $132.49M Feb 25, 2021
FY2019 Dec 31, 2017 $64.22M Feb 28, 2020
FY2018 Dec 31, 2016 $80.94M Mar 14, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $69.83M Feb 27, 2026
FY2025 Dec 31, 2024 $80.25M Feb 27, 2026
FY2025 Dec 31, 2023 $83.56M Feb 27, 2026
FY2024 Dec 31, 2022 $93.68M Feb 26, 2025
FY2023 Dec 31, 2021 $52.79M Feb 26, 2024
FY2022 Dec 31, 2020 $41.46M Feb 24, 2023
FY2021 Dec 31, 2019 $67.36M Feb 25, 2022
FY2020 Dec 31, 2018 $81.58M Feb 25, 2021
FY2019 Dec 31, 2017 $85.51M Feb 28, 2020
FY2018 Dec 31, 2016 $71.24M Mar 14, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.72B Feb 27, 2026
FY2025 Dec 31, 2024 $1.65B Feb 27, 2026
FY2025 Dec 31, 2023 $1.84B Feb 27, 2026
FY2024 Dec 31, 2022 $1.64B Feb 26, 2025
FY2023 Dec 31, 2021 $1.56B Feb 26, 2024
FY2022 Dec 31, 2020 $1.55B Feb 24, 2023
FY2021 Dec 31, 2019 $1.47B Feb 25, 2022
FY2020 Dec 31, 2018 $1.42B Feb 25, 2021
FY2019 Dec 31, 2017 $1.36B Feb 28, 2020
FY2018 Dec 31, 2016 $1.26B Mar 14, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $986.61M Feb 27, 2026
FY2025 Dec 31, 2024 $699.75M Feb 27, 2026
FY2024 Dec 31, 2023 $867.69M Feb 26, 2025
FY2023 Dec 31, 2022 $774.71M Feb 26, 2024
FY2022 Dec 31, 2021 $678.46M Feb 24, 2023
FY2021 Dec 31, 2020 $730.07M Feb 25, 2022
FY2020 Dec 31, 2019 $771.68M Feb 25, 2021
FY2019 Dec 31, 2018 $809.71M Feb 28, 2020
FY2018 Dec 31, 2017 $788.18M Mar 14, 2019
FY2017 Dec 31, 2016 $752.14M Feb 28, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $726.21M Feb 27, 2026
FY2025 Dec 31, 2024 $943.54M Feb 27, 2026
FY2024 Dec 31, 2023 $961.37M Feb 26, 2025
FY2023 Dec 31, 2022 $863.05M Feb 26, 2024
FY2022 Dec 31, 2021 $873.97M Feb 24, 2023
FY2021 Dec 31, 2020 $816.07M Feb 25, 2022
FY2020 Dec 31, 2019 $698.68M Feb 25, 2021
FY2019 Dec 31, 2018 $605.25M Feb 28, 2020
FY2018 Dec 31, 2017 $569.77M Mar 14, 2019
FY2017 Dec 31, 2016 $507.52M Feb 28, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $162.51M Feb 27, 2026
FY2025 Dec 31, 2024 $176.26M Feb 27, 2026
FY2024 Dec 31, 2023 $180.18M Feb 26, 2025
FY2023 Dec 31, 2022 $178.22M Feb 26, 2024
FY2023 Dec 31, 2021 $182.12M Feb 26, 2024
FY2022 Dec 31, 2020 $187.55M Feb 24, 2023
FY2021 Dec 31, 2019 $180.93M Feb 25, 2022
FY2019 Nov 20, 2019 $17.30M Feb 28, 2020
FY2020 Dec 31, 2018 $164.38M Feb 25, 2021
FY2019 Dec 31, 2017 $166.80M Feb 28, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $976.37M Feb 27, 2026
FY2025 Dec 31, 2024 $1.07B Feb 27, 2026
FY2024 Dec 31, 2023 $1.01B Feb 26, 2025
FY2023 Dec 31, 2022 $931.32M Feb 26, 2024
FY2022 Dec 31, 2021 $863.06M Feb 24, 2023
FY2021 Dec 31, 2020 $770.75M Feb 25, 2022
FY2020 Dec 31, 2019 $698.50M Feb 25, 2021
FY2019 Dec 31, 2018 $589.65M Feb 28, 2020
FY2018 Dec 31, 2017 $534.08M Mar 14, 2019
FY2017 Dec 31, 2016 $522.86M Feb 28, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $112.35M Feb 27, 2026
FY2025 Dec 31, 2024 $115.28M Feb 27, 2026
FY2024 Dec 31, 2023 $173.42M Feb 26, 2025
FY2023 Dec 31, 2022 $291.78M Feb 26, 2024
FY2022 Dec 31, 2021 $302.04M Feb 24, 2023
FY2021 Dec 31, 2020 $241.32M Feb 25, 2022
FY2020 Dec 31, 2019 $195.54M Feb 25, 2021
FY2019 Dec 31, 2018 $197.76M Feb 28, 2020
FY2019 Dec 31, 2017 $183.73M Feb 28, 2020
FY2019 Dec 31, 2016 $181.74M Feb 28, 2020

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $455.66M Feb 27, 2026
FY2025 Dec 31, 2024 $318.53M Feb 27, 2026
FY2024 Dec 31, 2023 $456.89M Feb 26, 2025
FY2023 Dec 31, 2022 $439.00M Feb 26, 2024
FY2021 Dec 31, 2021 $350.00M Feb 25, 2022
FY2021 Dec 31, 2020 $398.01M Feb 25, 2022
FY2020 Dec 31, 2019 $424.03M Feb 25, 2021
FY2019 Dec 31, 2018 $524.93M Feb 28, 2020
FY2018 Dec 31, 2017 $515.92M Mar 14, 2019
FY2017 Dec 31, 2016 $484.58M Feb 28, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Feb 27, 2026
FY2025 Dec 31, 2024 2 Feb 27, 2026
FY2025 Dec 31, 2023 3 Feb 27, 2026
FY2024 Dec 31, 2022 3 Feb 26, 2025
FY2023 Dec 31, 2021 3 Feb 26, 2024
FY2022 Dec 31, 2020 3 Feb 24, 2023
FY2019 Dec 31, 2019 0 Feb 28, 2020
FY2019 Sep 30, 2019 1 Feb 28, 2020
FY2019 Jun 30, 2019 1 Feb 28, 2020
FY2019 Mar 31, 2019 0 Feb 28, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Feb 27, 2026
FY2025 Dec 31, 2024 2 Feb 27, 2026
FY2025 Dec 31, 2023 3 Feb 27, 2026
FY2024 Dec 31, 2022 3 Feb 26, 2025
FY2023 Dec 31, 2021 3 Feb 26, 2024
FY2022 Dec 31, 2020 3 Feb 24, 2023
FY2019 Dec 31, 2019 0 Feb 28, 2020
FY2019 Sep 30, 2019 1 Feb 28, 2020
FY2019 Jun 30, 2019 1 Feb 28, 2020
FY2019 Mar 31, 2019 0 Feb 28, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 31.10M Feb 26, 2025
FY2024 Dec 31, 2023 31.20M Feb 26, 2025
FY2024 Dec 31, 2022 31.10M Feb 26, 2025
FY2023 Dec 31, 2021 32.10M Feb 26, 2024
FY2022 Dec 31, 2020 32.30M Feb 24, 2023
FY2021 Dec 31, 2019 32.30M Feb 25, 2022
FY2020 Dec 31, 2018 32.30M Feb 25, 2021
FY2019 Dec 31, 2017 32.20M Feb 28, 2020
FY2018 Dec 31, 2016 32.10M Mar 14, 2019
FY2017 Dec 31, 2015 32.00M Feb 28, 2018